Entree Health
Entrée Health is a market access and reimbursement agency dedicated to helping healthcare companies achieve market access success. Recognized as the 2023 and 2024 MM+M Market Access Agency of the Year, they bring experience, creativity, and a passion for healthcare access. Their services include value and HEOR communications, reimbursement support, brand planning, training, and analytics. They also offer innovative products like Access Next, a platform designed to streamline coverage and reimbursement conversations, integrated with sales systems like Veeva and Salesforce. With offices in New York, Princeton, and Boston, and service bureaus in Los Angeles and Seattle, they serve clients across the U.S.
Industries
Nr. of Employees
medium (51-250)
Entree Health
New York, New York, United States, North America
Products
Coverage and access data platform (sales integration)
A pull-through platform that delivers provider-specific coverage dashboards, customized messaging informed by provider insights, pre-call planning templates, integration with CRM/commercial systems, and tailored reporting for marketing and sales.
Coverage and access data platform (sales integration)
A pull-through platform that delivers provider-specific coverage dashboards, customized messaging informed by provider insights, pre-call planning templates, integration with CRM/commercial systems, and tailored reporting for marketing and sales.
Services
Consulting services to evaluate reimbursement potential, design market access strategies, and plan commercialization across payer types.
Development and validation of value platforms, evidence audits, and optimization of hub/patient support services to support access.
Opportunity assessment, bespoke market research, campaign effectiveness measurement, and media channel optimization to inform access campaigns.
Workshop design and facilitation, AE/KAM value training, and advisory boards including mock P&T and VAC sessions.
Brand planning, identity development, copywriting, medical editorial, and creation of provider-facing messaging and materials.
Consulting services to evaluate reimbursement potential, design market access strategies, and plan commercialization across payer types.
Development and validation of value platforms, evidence audits, and optimization of hub/patient support services to support access.
Opportunity assessment, bespoke market research, campaign effectiveness measurement, and media channel optimization to inform access campaigns.
Workshop design and facilitation, AE/KAM value training, and advisory boards including mock P&T and VAC sessions.
Brand planning, identity development, copywriting, medical editorial, and creation of provider-facing messaging and materials.
Expertise Areas
- Market access and reimbursement
- Health economics and outcomes research (HEOR)
- Access analytics and coverage data platforms
- Commercial pricing and contracting strategy
Key Technologies
- Coverage data platforms
- CRM and commercial system integration
- Cloud-based dashboards and reporting
- HEOR methodologies and value platforms
News & Updates
Utilizing a CMS 2018 policy update, UnitedHealthcare is applying step therapy to select Medicare Part B drug classes beginning in 2019, potentially influencing other plan sponsors.
The Trump Administration's proposed IPI payment model for Medicare Part B drugs aims to lower prescription drug prices.
Gilead is pursuing authorized generics for its HCV drugs Harvoni and Epclusa, which may become more common due to legislation regarding rebates.
Diversity and inclusion can help pharma reach larger, more diverse populations and improve population health.
The plan may include demonstration projects, waivers, and experiments to lower drug prices for Medicare beneficiaries.
MM+M Market Access Agency of the Year 2023 + 2024
Named the Market Access Agency of the Year by MM+M for 2023 and 2024.
Utilizing a CMS 2018 policy update, UnitedHealthcare is applying step therapy to select Medicare Part B drug classes beginning in 2019, potentially influencing other plan sponsors.
The Trump Administration's proposed IPI payment model for Medicare Part B drugs aims to lower prescription drug prices.
Gilead is pursuing authorized generics for its HCV drugs Harvoni and Epclusa, which may become more common due to legislation regarding rebates.
Diversity and inclusion can help pharma reach larger, more diverse populations and improve population health.
The plan may include demonstration projects, waivers, and experiments to lower drug prices for Medicare beneficiaries.
MM+M Market Access Agency of the Year 2023 + 2024
Named the Market Access Agency of the Year by MM+M for 2023 and 2024.